SureTrader Advertisement Advertisement Advertisement
Home > Boards > US OTC > Biotechs >

Talon Therapeutics, Inc. (TLON)

Add TLON Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 10/1/2015 5:41:59 PM - Followers: 107 - Board type: Free - Posts Today: 0



is since dec. 2010


Company Overview

Talon Therapeutics, Inc. is a San Francisco Bay Area-based biopharmaceutical company dedicated to seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring value to patients, patient care providers, shareholders, corporate partners, and employees.
Talon Therapeutics, Inc.
2207 Bridgepointe Parkway
Suite 250
San Mateo, CA 94404
United States -" rel="nofollow">Map
Phone:                650-588-6404       
Fax: 650-588-2787

Business Summary  

Talon Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing products for the foundation of cancer care. Its lead product candidate, Marqibo (vincristine sulfate liposomes injection), is a targeted Optisome encapsulated formulation product candidate, which is in the development for the treatment of adult acute lymphoblastic leukemia. The company's product candidates also include Menadione Topical Lotion, a supportive care product candidate that completed Phase 1 clinical trial for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors, a type of anti-cancer agent used in the treatment of lung, colon, head and neck, pancreatic, and breast cancer; and Brakiva (topotecan liposomes injection), a targeted Optisome encapsulated formulation product candidate for the treatment of metastatic carcinoma of the ovary and small cell lung cancer. In addition, its development stage product consists of Alocrest (vinorelbine liposomes injection), a targeted Optisome encapsulated formulation product candidate for the treatment of solid tumors, such as non-small-cell lung cancer. Optisomal encapsulation is a method of liposomal drug delivery, which is designed to increase tumor targeting and duration of exposure for cell-cycle specific anticancer agents. The company was formerly known as Hana Biosciences, Inc. and changed its name to Talon Therapeutics, Inc. in December 2010. Talon Therapeutics, Inc. was founded in 2002 and is based in San Mateo, California


Current Pipeline




Marqibo® (vincristine sulfate liposomes injection, OPTISOME™)
A Novel Targeted Nanoparticle-encapsulated Anti-Cancer Compound currently for Acute Lymphoblastic Leukemia (ALL) and Melanoma. Marqibo® has a robust safety database (over 600 patients) and has been extensively evaluated in lymphoid blood cancers such as non-Hodgkin's lymphoma (NHL) and ALL. Hana has ongoing (or planned) clinical trials which may enable an accelerated approval in 2 indications. Future clinical trial development possible in multiple indications including NHL and melanoma. More Details »

Alocrest™ (vinorelbine liposomes injection, OPTISOME™)
A Novel Targeted Anti-Cancer Compound for Breast and Lung Cancer. Alocrest™ has completed a Phase I dose-escalation trial demonstrating promising anti-cancer activity as well as acceptable and predictable toxicity. More Details »

Brakiva™ (topotecan liposomes injection, OPTISOME™)
A Novel Targeted Anti-Cancer Compound for Small-Cell Lung Cancer and Ovarian Cancer. Preclinical data demonstrate the value of Brakiva™ over conventional topotecan. More Details »

Menadione Topical Lotion - A Topical Compound for Skin Rash Associated with EGFR Inhibitors. Treatment with EGFR inhibitors such as Tarceva®, Erbitux® and Vectibix® are associated with an acne-form rash involving the face, neck and upper torso in approximately 75% patients. 50% of patients who manifest skin toxicity experience significant discomfort. This results in drug discontinuation or dose reduction in at least 10% and up to 30% of all subjects. Drug delivery is targeted to the normal location of the EGFR-containing skin cells at the dermal/epidermal junction without interfering with EGFR inhibition systemically at the level of the tumor. More Details »


Talon Therapeutics Corporate Presentation   PDF 869.6 KB Add to Briefcase

VSLI (Vincristine Sulfate Liposomes Injection, Marqibo®) "Bridging" to Potentially Curative Hematopoietic Stem Cell Transplantation (HSCT) in Adults with Philadelphia Chromosome Negative (PH-) Acute Lymphoblastic Leukemia (ALL) 06/09/2011 PDF 151.1 KB Add to Briefcase
VSLI (vincristine sulfate liposomes injection) in the Treatment of Adult Subjects with Advanced, Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL): A Combined Analysis of the VSLI-06 and rALLy Studies 12/05/2010 PDF 110.6 KB Add to Briefcase
Marqibo (vincristine sulfate liposomes injection; VSLI) Optimizes the Dosing, Delivery, and Pharmacokinetic (PK) Profile of Vincristine Sulfate (VCR) in Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL) 12/05/2010 PDF

and more:


  • OTC Market Tier

    Pink Quote/OTCBB
  • Primary SIC - Industry Classification

    2834 - Pharmaceutical preparations
  • State Of Incorporation

  • Jurisdiction Of Incorporation

    United States



Board of Directors

Steven R. Deitcher, M.D.
President & Chief Executive Officer

Nishan de Silva, M.D.
Principal, Warburg Pincus

Andrew K. Ferrer
Associate, Warburg Pincus

Howard P. Furst, M.D.
Partner, Deerfield Management

Jonathan S. Leff
Managing Director, Warburg Pincus

Paul V. Maier
Chief Financial Officer, Sequenom, Inc.

Leon E. Rosenberg, M.D. (Chairman)
Professor of Molecular Biology, Princeton University

Robert J. Spiegel, M.D.


  • SEC Reporting Status

    SEC Reporting Company
  • CIK

  • Fiscal Year End


Current Share Structure

Current as of 12/31/2010

A/S 350,000,000

O/S 21,242,772 (Mar 28, 2011)

FLOAT  16.48M

Transfer Agent

Corporate Stock Transfer, Inc.
3200 Cherry Creek Drive South
Denver, CO 80209


 Recent news


Tuesday, August 9, 2011

Wednesday, July 20, 2011

Tuesday, July 19, 2011

Monday, July 18, 2011

Friday, July 1, 2011

Thursday, June 30, 2011

Friday, June 17, 2011

Monday, June 6, 2011

Thursday, May 19, 2011

Friday, May 13, 2011

Tuesday, May 10, 2011

Monday, May 9, 2011

Monday, March 28, 2011

Thursday, March 24, 2011

Monday, March 14, 2011

Thursday, March 10, 2011

Wednesday, January 12, 2011





New presentation from tlon from 3-30-12

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
TLON News: Confidential Treatment Order (ct Order) 09/18/2015 01:51:21 PM
#5934   We can call Spectrum Pharma investor relations at FLY HIGH NOW 10/01/15 05:41:59 PM
#5933   WHERE ARE OUR CVR? FLY HIGH NOW 09/25/15 12:00:33 AM
#5932   so we TLON Shareholders get how much from FLY HIGH NOW 07/30/15 11:07:15 AM
#5931   revenue marqibo 1.Q 2015 1.9 million vs 1.5 upanddown66 07/26/15 03:44:18 AM
#5930   God bless TLON FLY HIGH NOW 06/25/15 08:56:29 AM
#5929   Still waiting for some Miracle. xlofer 06/20/15 02:04:58 AM
#5928   We are TLON Shareholders not receive anything from SPECTRUM? FLY HIGH NOW 06/19/15 09:08:29 PM
#5927   I dont envision ever getting money back for chicken_nguyen 03/12/15 12:55:40 PM
#5926   Any one hears anything from Spectrum about TLON FLY HIGH NOW 02/11/15 08:10:12 PM
#5925   We TLON haven't received any penny or dime FLY HIGH NOW 01/28/15 08:17:47 AM
#5924   anyone knows or hears anything about TLON DRUG FLY HIGH NOW 12/26/14 02:47:22 AM
#5923   when is the next q folks dmb17 09/21/14 05:12:09 AM
#5922   Spectrum Pharmaceuticals Reports 45% Sales Growth for FLY HIGH NOW 08/08/14 10:20:57 AM
#5921   SPECTRUM REVENUE??? FLY HIGH NOW 08/04/14 10:06:57 AM
#5920   Hello anyone see anything from them? how much FLY HIGH NOW 07/29/14 10:14:14 AM
#5919   we could se it oin the 10Q 's 10bags 06/27/14 11:16:12 AM
#5918   I HOPE WE SEE $400 MIL SOLD SOON FLY HIGH NOW 06/27/14 10:29:35 AM
#5917   Year Ended December 31, 10bags 05/11/14 06:34:01 PM
#5916   when you got any paypment or you found 10bags 05/11/14 06:27:39 PM
#5914   they said that we should review Section FLY HIGH NOW 03/28/14 12:43:27 AM
#5913   Yep about to see my accountant, 29k hit Built4Sin 03/26/14 05:04:26 PM
#5912   i´m not from the usa can someone do 10bags 03/26/14 03:24:04 PM
#5910   yes this is the problem can nayone call 10bags 03/07/14 12:04:48 PM
#5909   Marqibo net sales Q4 2013 were reported as eandersen2 03/07/14 11:27:55 AM
#5906   Not a clue. Can't seem to find the eandersen2 11/26/13 05:48:23 PM
#5905   you have any clue on the milestones for 10bags 11/26/13 04:57:11 PM
#5904   oh they still sell it nice 10bags 11/21/13 11:48:00 AM
#5903   Net sales for Marqibo Q3 was 100K eandersen2 11/21/13 11:09:58 AM
#5902   Spectrum Pharmaceuticals to Present Corporate Update at the 10bags 11/11/13 05:57:40 PM
#5901   Since they never published the milestones I would ErnieBilco 09/26/13 12:44:14 AM
#5900   is there any infos about the CVR and 10bags 09/26/13 12:30:38 AM
#5899   They are valued at ZERO but are sitting ErnieBilco 09/18/13 06:53:18 PM
#5898   Anyone here?? Anything about CVR??? gooddaystocome 09/18/13 03:37:19 PM
#5897   So Spectrum did in a couple of months ErnieBilco 09/10/13 09:00:06 AM
#5896   Spectrum has launched Marqibo. Does anyone have papag02 09/10/13 06:58:14 AM
#5895   Hello stranger pnew122 09/04/13 09:16:19 PM
#5894   this is great; it cost me $20 viki 09/03/13 09:15:37 AM
#5893   Yes, I see it. gooddaystocome 08/22/13 09:38:50 PM
#5892   Nothing in mail. In my fidelity acct it Dcdc47 08/22/13 08:31:05 AM
#5891   I've only received nickel in account but no cvr. gooddaystocome 08/22/13 02:16:19 AM
#5890   Now that I lost money on this debacle ErnieBilco 08/21/13 11:16:50 PM
#5889   I got both nickel and cvr...moved on and Dcdc47 08/20/13 12:45:57 PM
#5888   I also received the .056 per share in f15eagle 08/19/13 10:07:38 PM
#5887   I also received the .056 per share in f15eagle 08/19/13 10:07:06 PM
#5886   95% loss xlofer 08/19/13 07:49:05 PM
#5885   I received $.056 a share in my account today. xlofer 08/19/13 07:48:39 PM